References
- https://coronavirus.jhu.edu/map.html
- Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine
and its clinical implications in chemoprophylaxis against malaria
caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009
Apr;53(4):1468-75. doi: 10.1128/AAC.00339-08. Epub 2009 Feb 2. PubMed
PMID: 19188392; PubMed Central PMCID: PMC2663072.
- Carmichael SJ, Charles B, Tett SE. Population Pharmacokinetics of
Hydroxychloroquine in Patients with Rheumatoid Arthritis. Ther Drug
Monit. 2003
Dec;25(6):671-81. PubMed PMID: 14639053.
- Morita S, Takahashi T, Yoshida Y, Yokota N. Population
pharmacokinetics of hydroxychloroquine in Japanese patients with
cutaneous or systemic lupus erythematosus. Ther Drug Monit.
2016;38:259–67.
- Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral
Activity and Projection of Optimized Dosing Design of
Hydroxychloroquine for the Treatment of Severe Acute Respiratory
Syndrome Main point : Hydroxychloroquine was found to be more potent
than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis.
2020;2:1–25.
- Gautret al. Hydroxychloroquine and azithromycin as a treatment of
COVID-19: results of an open-label non-randomized clinical trial.
International Journal of Antimicrob Agents – In Press 17 March 2020.
– DOI: 10.1016/j.ijantimicag.2020.105949
- Gautret P, Lagier JP, Parola P et al. Clinical and microbiological
effect of a combination of hydroxychloroquine and azithromycin in 80
COVID-19 patients with at least a six-day follow up: an observational
study. (2020)
- Chen J, Liu D, Lui L, et al. A pilot study of hydroxychloroquine in
treatment of patients with common coronavirus disease-19 COVID-19).
Journal of Zhejiang University 2020; 03-03
- Zhaowei Chen, Jijia Hu, Zongwei Zhang, et al. Efficacy of
hydroxychloroquine in patients with COVID-19: results of a randomized
clinical trial. medRxiv 2020.03.22.20040758; doi:
https://doi.org/10.1101/2020.03.22.20040758)http://kns.cnki.net/kcms/detail/33.1248.R.20200309.1507.006.html
- Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt
L, de Castro N, No Evidence of Rapid Antiviral Clearance or Clinical
Benefit with the Combination of Hydroxychloroquine and Azithromycin in
Patients with Severe COVID-19 Infection, Medecine et Maladies
Infectieuses (2020), doi: https://doi.org/10.1016/j.medmal.2020.03.006
- https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
- Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing
hydroxychloroquine dosing for patients with COVID-19: An integrative.
Clin Pharmacol Ther 2020 (in press)
- Lim et al. Pharmacokinetics of Hydroxychloroquine and Its Clinical
Implications in hemoprophylaxis against Malaria Caused by Plasmodium
vivax. Antimicrob Agents Chemother. Apr 2009; 53 (4):
1468-1475.Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine:
balancing the need to maintain therapeutic levels with ocular safety:
an update. Curr Opin Rheumatol. 2018 May;30(3):249-255. doi:
10.1097/BOR.0000000000000500. Review. PubMed PMID: 29517495.
- Tett SE et al. Bioavailability of hydroxychloroquine tablets in
healthy volunteers. Br J Clin Pharmacol. 1989 Jun;27(6):771-9.
- Balevic SJ et al. Pharmacokinetics of Hydroxychloroquine in
Pregnancies with Rheumatic Diseases. Clin Pharmacokinet. 2019
Apr;58(4):525-533.
- Blanchet B, Moez J, Allard M, le guern vet al. Hydroxychloroquine
Levels in Patients with Systemic Lupus Erythematosus: Comparison of
Whole Blood and Serum Levels [abstract]. Arthritis Rheumatol.
2019; 71 (suppl 10).
https://acrabstracts.org/abstract/hydroxychloroquine-levels-in-patients-with-systemic-lupus-erythematosus-comparison-of-whole-blood-and-serum-levels/.
Accessed April 20, 2020.
- Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic;Lancet 2020; 395: 391–93
- Zheng, Y., Ma, Y., Zhang, J. et al. COVID-19 and the cardiovascular
system. Nat Rev Cardiol (2020).
https://doi.org/10.1038/s41569-020-0360-5
- Wu C-I, Postema PG, Arbelo E, Behr ER, Bezzina CR, Napolitano C,
Robyns T, Probst V, Schulze-Bahr E, Remme CA, Wilde AAM, SARS-CoV-2,
COVID-19 and inherited arrhythmia syndromes, Heart Rhythm (2020), doi:
https://doi.org/10.1016/j.hrthm.2020.03.024.